Prophylaxis in a Patch - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prophylaxis in a Patch
New studies reveal the promise and feasibility of transdermal vaccine delivery.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 14


Erik Greb
The growth in the biologics market has given the industry an extra incentive to find painless ways of administering vaccines. Recent animal studies indicate that the transdermal route could be a viable option.

Researchers from the Georgia Institute of Technology vaccinated mice against influenza using patches that contained dissolving microneedles. This administration method provided at least as much protection as traditional hypodermic injections, according to their July 2010 article in Nature Medicine.

A $10-million grant from the National Institutes of Health will enable the researchers, in cooperation with Emory University, to develop the patch further and conduct a Phase I clinical trial. The patch uses a dry form of the vaccine, and the team will study its stability to determine whether it can be stored without refrigeration.

Another goal of the study is to ensure that the patch is simple and reliable enough for any patient to use without assistance, says Mark Prausnitz, the project's principal investigator. If the study is successful, the patch eventually could become a more popular delivery device than autoinjectors.

Until recently, transdermal delivery had been restricted to small and lipophilic molecules. Projects such as Prausnitz's open the possibility that vaccines and other large-molecule drugs could be given effectively through the skin. Such easy and painless administration could have big benefits for public health. For needlephobes and drug-delivery scientists alike, the prospects are exciting.

Erik Greb is an associate editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here